Novo Nordisk: complaint from shareholders filed in Denmark
(CercleFinance.com) - A complaint has been filed against Novo Nordisk by shareholders accusing the Danish pharmaceutical group of "misleading statements" about its insulin sales in the United States.
The complaint - filed in Denmark - argues that Novo Nordisk has not provided adequate information on sales of its insulin drugs marketed in the United States.
The laboratory notes that the plaintiffs - who bought their Novo Nordisk shares between February 2015 and 2017 - invoked facts similar to those raised during a US-led class action lawsuit in 2017 by holders of its ADR.
In a statement released on Friday, Novo Nordisk refutes these allegations and says it intends to defend itself.
Copyright (c) 2019 CercleFinance.com. All rights reserved.